Table 1.

Summary of examined studies.

Reference	Patient population receiving GO	DF as prophylaxis		Outcome of VOD/SOS with DF treatment
		Number of patients	Incidence of VOD/SOS
PubMed search
Battipaglia et al. 2017¹⁴	Retrospective; HCT in 146 adults	4 patients	2 developed VOD/SOS	VOD/SOS treated with DF in 2 patients; both survived (1 received prophylaxis with DF, the other received heparin)
Richardson et al. 2010¹⁵	20 adult and pediatric patients with VOD/SOS and MOD	—	—	All received DF (phase 2 dose-finding study); Day 100 survival was 50% (n = 10/20); trend toward higher CR rate in GO subgroup
Zwaan et al. 2010¹⁶	30 pediatric patients treated for AML relapse	8 patients	No cases of VOD/SOS	—
Bornhäuser et al. 2008¹⁷	31 patients with refractory AML	—	—	1 case of VOD/SOS after HCT; treated successfully with DF
Lannoy et al. 2006¹⁸	1 patient treated for relapsed AML	—	—	DF deemed effective in treating symptoms of VOD/SOS; death attributed to GO failure
Reinhardt et al. 2004¹⁹	12 pediatric patients treated for relapsed AML	—	—	1 patient with VOD/SOS treated successfully with DF
Versluys et al. 2004²⁰	7 patients treated for relapsed AML prior to HCT	6 patients	No cases of VOD/SOS	1 patient without DF prophylaxis had severe VOD/SOS, which was successfully treated with DF
Saviola et al. 2003²¹	1 adult with refractory AML	—	—	VOD/SOS treated successfully with DF
Congress report identified separately from PubMed search
Corbacioglu et al. 2015²²^a	16 pediatric patients at high risk of VOD/SOS prior to HCT	11 patients	2 developed VOD/SOS	—

^aThis ASH abstract reporting a study of 356 patients was not included in the analysis, which focused on published manuscripts in PubMed.

GO gemtuzumab ozogamicin, DF defibrotide, VOD/SOS veno-occlusive disease/sinusoidal obstruction syndrome, HCT hematopoietic cell transplantation, MOD multi-organ dysfunction, CR complete response, AML acute myeloid leukemia.